Stefan P Tarnawsky1, Momoko Yoshimoto1, Lisa Deng2, Rebecca J Chan2,3, Mervin C Yoder1,3. 1. Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana. 2. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana. 3. Department of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
BACKGROUND: Accumulating evidence suggests the origin of juvenile myelomonocytic leukemia (JMML) is closely associated with fetal development. Nevertheless, the contribution of embryonic progenitors to JMML pathogenesis remains unexplored. We hypothesized that expression of JMML-initiating PTPN11 mutations in HSC-independent yolk sac erythromyeloid progenitors (YS EMPs) would result in a mouse model of pediatric myeloproliferative neoplasm (MPN). RESULTS: E9.5 YS EMPs from VavCre+;PTPN11D61Y embryos demonstrated growth hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and hyperactive RAS-ERK signaling. Mutant EMPs engrafted the spleens of neonatal recipients, but did not cause disease. To assess MPN development during unperturbed hematopoiesis we generated CSF1R-MCM+;PTPN11E76K ;ROSAYFP mice in which oncogene expression was restricted to EMPs. Yellow fluorescent protein-positive progeny of mutant EMPs persisted in tissues one year after birth and demonstrated hyperactive RAS-ERK signaling. Nevertheless, these mice had normal survival and did not demonstrate features of MPN. CONCLUSIONS: YS EMPs expressing mutant PTPN11 demonstrate functional and molecular features of JMML but do not cause disease following transplantation nor following unperturbed development. Developmental Dynamics 246:1001-1014, 2017.
BACKGROUND: Accumulating evidence suggests the origin of juvenile myelomonocytic leukemia (JMML) is closely associated with fetal development. Nevertheless, the contribution of embryonic progenitors to JMML pathogenesis remains unexplored. We hypothesized that expression of JMML-initiating PTPN11 mutations in HSC-independent yolk sac erythromyeloid progenitors (YS EMPs) would result in a mouse model of pediatric myeloproliferative neoplasm (MPN). RESULTS: E9.5 YS EMPs from VavCre+;PTPN11D61Y embryos demonstrated growth hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) and hyperactive RAS-ERK signaling. Mutant EMPs engrafted the spleens of neonatal recipients, but did not cause disease. To assess MPN development during unperturbed hematopoiesis we generated CSF1R-MCM+;PTPN11E76K ;ROSAYFP mice in which oncogene expression was restricted to EMPs. Yellow fluorescent protein-positive progeny of mutant EMPs persisted in tissues one year after birth and demonstrated hyperactive RAS-ERK signaling. Nevertheless, these mice had normal survival and did not demonstrate features of MPN. CONCLUSIONS: YS EMPs expressing mutant PTPN11 demonstrate functional and molecular features of JMML but do not cause disease following transplantation nor following unperturbed development. Developmental Dynamics 246:1001-1014, 2017.
Authors: Lei Dong; Wen-Mei Yu; Hong Zheng; Mignon L Loh; Silvia T Bunting; Melinda Pauly; Gang Huang; Muxiang Zhou; Hal E Broxmeyer; David T Scadden; Cheng-Kui Qu Journal: Nature Date: 2016-10-26 Impact factor: 49.962
Authors: Raquel Espín-Palazón; David L Stachura; Clyde A Campbell; Diana García-Moreno; Natasha Del Cid; Albert D Kim; Sergio Candel; José Meseguer; Victoriano Mulero; David Traver Journal: Cell Date: 2014-11-06 Impact factor: 41.582
Authors: Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: Ben A Croker; Donald Metcalf; Lorraine Robb; Wei Wei; Sandra Mifsud; Ladina DiRago; Leonie A Cluse; Kate D Sutherland; Lynne Hartley; Emily Williams; Jian-Guo Zhang; Douglas J Hilton; Nicos A Nicola; Warren S Alexander; Andrew W Roberts Journal: Immunity Date: 2004-02 Impact factor: 31.745
Authors: Franco Locatelli; Alessandro Crotta; Annalisa Ruggeri; Mary Eapen; John E Wagner; Margaret L Macmillan; Marco Zecca; Joanne Kurtzberg; Carmem Bonfim; Ajay Vora; Cristina Díaz de Heredia; Lochie Teague; Jerry Stein; Tracey A O'Brien; Henrique Bittencourt; Adrienne Madureira; Brigitte Strahm; Christina Peters; Charlotte Niemeyer; Eliane Gluckman; Vanderson Rocha Journal: Blood Date: 2013-08-07 Impact factor: 22.113
Authors: Sasja Blokzijl-Franke; Florian Piques; Maja Solman; Chuan Yan; Qiqi Yang; Marion Strullu; Sarah M Kamel; Pakize Ak; Jeroen Bakkers; David M Langenau; Hélène Cavé; Jeroen den Hertog Journal: Elife Date: 2022-05-10 Impact factor: 8.713
Authors: Anna Cazzola; Giovanni Cazzaniga; Andrea Biondi; Raffaella Meneveri; Silvia Brunelli; Emanuele Azzoni Journal: Front Cell Dev Biol Date: 2021-01-12